AR and neoplasm: AR antagonist in vitro testing in five different LAR cell line models showed high sensitivity to 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) and bicalutamide treatment, thus indicating that AR targeting therapies may be effective against LAR tumours [14].